Pharmacovigilance in oncology

Paolo Baldo, Giulia Fornasier, Laura Ciolfi, Ivana Sartor, Sara Francescon

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Background Side effects of cancer therapy are one of the most important issues faced by cancer patients during their illness. Pharmacovigilance, namely the science and activities aimed at monitoring the safety of drugs, is particularly important in oncology, due to the intrinsic biologic toxicity of antineoplastic agents, their narrow therapeutic windows, and the high doses and rigid timing of treatment regimens. Aim of the review To identify the main issues in carrying out an effective pharmacovigilance activity in oncology. Method We searched PubMed for articles about pharmacovigilance in relation to chemotherapy, radiotherapy and targeted therapy for cancer, using MeSH terms and text words. We also searched Embase, CINAHL, Scopus, Micromedex, the Cochrane Library, two pharmacovigilance databases and the gray literature for articles published in 2012–2018. Overall, 137 articles were considered potentially relevant and were critically appraised independently by two authors, leading to the inclusion of 44 relevant studies, guidelines and reviews. Another 10 important research reports were included in the review. Results Eight critical issues of pharmacovigilance in oncology were identified. These issues pertain to: terminology; range of side effects; targeted therapy and immunotherapy; chemoradiotherapy; generic drugs and biosimilars; drug interactions, pharmacogenetics and polypharmacy; special patient categories; and under-reporting of ADRs. Conclusion The importance of pharmacovigilance in oncology must be highlighted with every effort, to improve safety and offer cancer patients every possible help to improve their quality of life during such a critical period of their lives.

Original languageEnglish
Pages (from-to)832-841
Number of pages10
JournalInternational Journal of Clinical Pharmacy
Volume40
Issue number4
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Pharmacovigilance
Oncology
Biosimilar Pharmaceuticals
Chemoradiotherapy
Drug interactions
Generic Drugs
Chemotherapy
Neoplasms
Radiotherapy
Terminology
Antineoplastic Agents
Toxicity
Therapeutics
Safety
Polypharmacy
Drug Monitoring
Pharmacogenetics
Drug Interactions
PubMed
Immunotherapy

Keywords

  • Adverse drug reactions
  • Cancer
  • Cytotoxic chemotherapy
  • Neoplasms
  • Oncology
  • Pharmacovigilance
  • Radiotherapy
  • Safety
  • Targeted therapy
  • Toxicity

ASJC Scopus subject areas

  • Pharmacy
  • Toxicology
  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Pharmacovigilance in oncology. / Baldo, Paolo; Fornasier, Giulia; Ciolfi, Laura; Sartor, Ivana; Francescon, Sara.

In: International Journal of Clinical Pharmacy, Vol. 40, No. 4, 01.08.2018, p. 832-841.

Research output: Contribution to journalReview article

@article{de7f93df4d404226873fe1771c0d8d48,
title = "Pharmacovigilance in oncology",
abstract = "Background Side effects of cancer therapy are one of the most important issues faced by cancer patients during their illness. Pharmacovigilance, namely the science and activities aimed at monitoring the safety of drugs, is particularly important in oncology, due to the intrinsic biologic toxicity of antineoplastic agents, their narrow therapeutic windows, and the high doses and rigid timing of treatment regimens. Aim of the review To identify the main issues in carrying out an effective pharmacovigilance activity in oncology. Method We searched PubMed for articles about pharmacovigilance in relation to chemotherapy, radiotherapy and targeted therapy for cancer, using MeSH terms and text words. We also searched Embase, CINAHL, Scopus, Micromedex, the Cochrane Library, two pharmacovigilance databases and the gray literature for articles published in 2012–2018. Overall, 137 articles were considered potentially relevant and were critically appraised independently by two authors, leading to the inclusion of 44 relevant studies, guidelines and reviews. Another 10 important research reports were included in the review. Results Eight critical issues of pharmacovigilance in oncology were identified. These issues pertain to: terminology; range of side effects; targeted therapy and immunotherapy; chemoradiotherapy; generic drugs and biosimilars; drug interactions, pharmacogenetics and polypharmacy; special patient categories; and under-reporting of ADRs. Conclusion The importance of pharmacovigilance in oncology must be highlighted with every effort, to improve safety and offer cancer patients every possible help to improve their quality of life during such a critical period of their lives.",
keywords = "Adverse drug reactions, Cancer, Cytotoxic chemotherapy, Neoplasms, Oncology, Pharmacovigilance, Radiotherapy, Safety, Targeted therapy, Toxicity",
author = "Paolo Baldo and Giulia Fornasier and Laura Ciolfi and Ivana Sartor and Sara Francescon",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s11096-018-0706-9",
language = "English",
volume = "40",
pages = "832--841",
journal = "International Journal of Clinical Pharmacy",
issn = "2210-7703",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Pharmacovigilance in oncology

AU - Baldo, Paolo

AU - Fornasier, Giulia

AU - Ciolfi, Laura

AU - Sartor, Ivana

AU - Francescon, Sara

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Background Side effects of cancer therapy are one of the most important issues faced by cancer patients during their illness. Pharmacovigilance, namely the science and activities aimed at monitoring the safety of drugs, is particularly important in oncology, due to the intrinsic biologic toxicity of antineoplastic agents, their narrow therapeutic windows, and the high doses and rigid timing of treatment regimens. Aim of the review To identify the main issues in carrying out an effective pharmacovigilance activity in oncology. Method We searched PubMed for articles about pharmacovigilance in relation to chemotherapy, radiotherapy and targeted therapy for cancer, using MeSH terms and text words. We also searched Embase, CINAHL, Scopus, Micromedex, the Cochrane Library, two pharmacovigilance databases and the gray literature for articles published in 2012–2018. Overall, 137 articles were considered potentially relevant and were critically appraised independently by two authors, leading to the inclusion of 44 relevant studies, guidelines and reviews. Another 10 important research reports were included in the review. Results Eight critical issues of pharmacovigilance in oncology were identified. These issues pertain to: terminology; range of side effects; targeted therapy and immunotherapy; chemoradiotherapy; generic drugs and biosimilars; drug interactions, pharmacogenetics and polypharmacy; special patient categories; and under-reporting of ADRs. Conclusion The importance of pharmacovigilance in oncology must be highlighted with every effort, to improve safety and offer cancer patients every possible help to improve their quality of life during such a critical period of their lives.

AB - Background Side effects of cancer therapy are one of the most important issues faced by cancer patients during their illness. Pharmacovigilance, namely the science and activities aimed at monitoring the safety of drugs, is particularly important in oncology, due to the intrinsic biologic toxicity of antineoplastic agents, their narrow therapeutic windows, and the high doses and rigid timing of treatment regimens. Aim of the review To identify the main issues in carrying out an effective pharmacovigilance activity in oncology. Method We searched PubMed for articles about pharmacovigilance in relation to chemotherapy, radiotherapy and targeted therapy for cancer, using MeSH terms and text words. We also searched Embase, CINAHL, Scopus, Micromedex, the Cochrane Library, two pharmacovigilance databases and the gray literature for articles published in 2012–2018. Overall, 137 articles were considered potentially relevant and were critically appraised independently by two authors, leading to the inclusion of 44 relevant studies, guidelines and reviews. Another 10 important research reports were included in the review. Results Eight critical issues of pharmacovigilance in oncology were identified. These issues pertain to: terminology; range of side effects; targeted therapy and immunotherapy; chemoradiotherapy; generic drugs and biosimilars; drug interactions, pharmacogenetics and polypharmacy; special patient categories; and under-reporting of ADRs. Conclusion The importance of pharmacovigilance in oncology must be highlighted with every effort, to improve safety and offer cancer patients every possible help to improve their quality of life during such a critical period of their lives.

KW - Adverse drug reactions

KW - Cancer

KW - Cytotoxic chemotherapy

KW - Neoplasms

KW - Oncology

KW - Pharmacovigilance

KW - Radiotherapy

KW - Safety

KW - Targeted therapy

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85051531716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051531716&partnerID=8YFLogxK

U2 - 10.1007/s11096-018-0706-9

DO - 10.1007/s11096-018-0706-9

M3 - Review article

C2 - 30069667

AN - SCOPUS:85051531716

VL - 40

SP - 832

EP - 841

JO - International Journal of Clinical Pharmacy

JF - International Journal of Clinical Pharmacy

SN - 2210-7703

IS - 4

ER -